EPH Receptor A4 anticorps (C-Term)

N° du produit ABIN7877361

L’anticorps anti-EPH Receptor A4 Polyclonal Lapin est utilisé pour la détection de EPH Receptor A4 dans des échantillons de Humain. Il a été validé pour WB.

Aperçu rapide pour EPH Receptor A4 anticorps (C-Term) (ABIN7877361)

Antigène: EPH Receptor A4 (EPHA4)

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp EPH Receptor A4 est non-conjugé

Application: Western Blotting (WB)

Détail du produit anti-EPH Receptor A4 anticorps

Épitope: C-Term

Fonction: EPHA4 Antibody / Ephrin type-A receptor 4

Purification: Immunogen affinity purified

Immunogène: A synthetic peptide corresponding to a sequence at the C-terminus of human EPHA4 was used as the immunogen for the EPHA4 antibody.

Isotype: IgG

Information d'application

Indications d'application: Optimal dilution of the EPHA4 antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4.

Stock: 4 °C,-20 °C

Stockage commentaire: After reconstitution, the EPHA4 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Détails sur EPH Receptor A4

Antigène: EPH Receptor A4 (EPHA4)

Autre désignation: EPHA4

Sujet: EPHA4 antibody detects Ephrin type-A receptor 4, a receptor tyrosine kinase that mediates axon guidance, cell adhesion, and tissue patterning through bidirectional ephrin signaling. EPHA4 belongs to the Eph receptor family, the largest group of receptor tyrosine kinases in vertebrates. The EPHA4 antibody is used extensively in neuroscience, developmental biology, and cancer research to investigate cell-cell communication and guidance signaling.

EPHA4 is encoded by the EPHA4 gene on human chromosome 2q36.1. The receptor consists of an extracellular ligand-binding domain, a cysteine-rich region, two fibronectin type III repeats, a single transmembrane domain, and an intracellular kinase domain. EPHA4 binds both ephrin-A and ephrin-B ligands, enabling cross-class signaling that regulates axonal navigation, synaptic plasticity, and tissue boundary formation.

The EPHA4 antibody detects a 120-130 kilodalton transmembrane receptor by western blot. Activation of EPHA4 by ephrin ligands triggers receptor autophosphorylation, recruitment of adaptor proteins, and cytoskeletal reorganization via Rho GTPase signaling. This leads to growth cone collapse and repulsion, essential for proper neural circuit formation.

In the central nervous system, EPHA4 influences axon pathfinding in the corticospinal tract and regulates synapse formation and plasticity. It is also implicated in spinal cord injury response, where its inhibition promotes axonal regeneration. Outside the nervous system, EPHA4 modulates angiogenesis, epithelial morphogenesis, and tumor progression. Overexpression has been observed in breast, prostate, and colorectal cancers, correlating with invasive behavior and poor prognosis.

EPHA4 signaling crosstalks with pathways including MAPK, PI3K-Akt, and JAK-STAT, integrating environmental cues with cell motility and survival. Genetic ablation in animal models results in abnormal axon targeting and motor coordination defects. NSJ Bioreagents provides a validated EPHA4 antibody optimized for western blot, supporting comprehensive investigation of receptor tyrosine kinase signaling, neural development, and cancer cell dynamics.

UniProt: P54764

Pathways: Signalisation RTK